Description: Clearside BioMedical, Inc., a biopharmaceutical company, develops drug therapies to treat chronic blinding diseases of the eye. Its products include CLS-1001 for the treatment of macular edema associated with non-infectious uveitis; CLS-1003 for the treatment of macular edema associated with retinal vein occlusion; and CLS-1002 program for the treatment of wet age-related macular degeneration. The company was founded in 2011 and is headquartered in Alpharetta, Georgia.
Home Page: www.clearsidebio.com
CLSD Technical Analysis
900 North Point Parkway
Alpharetta,
GA
30005
United States
Phone:
678 270 3631
Officers
| Name | Title |
|---|---|
| Dr. George M. Lasezkay J.D., Pharm.D., Pharma.D. | Pres, CEO & Director |
| Mr. Charles A. Deignan | Chief Financial Officer |
| Dr. Thomas A. Ciulla M.B.A., M.D. | Chief Medical Officer & Chief Devel. Officer |
| Ms. Jenny R. Kobin | Head of Investor Relations |
| Mr. Rick McElheny | VP of Corp. Devel. |
| Ms. Susan L. Coultas Ph.D. | Chief Clinical Officer |
| Mr. Leslie B. Zacks | Sec. |
Exchange: NASDAQ
Country: US : United States of America
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Pharmaceuticals |
| GIC Sub-Industry: | Pharmaceuticals |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 161 |
| Price-to-Book MRQ: | 3.927 |
| Price-to-Sales TTM: | 2.6392 |
| IPO Date: | 2016-06-02 |
| Fiscal Year End: | December |
| Full Time Employees: | 34 |